What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31744 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2025. Written by Zachary L Taylor and 11 co-authors. Institution: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Major MEDLINE topics: Methotrexate, Drug Monitoring, Antimetabolites, Antineoplastic, Neoplasms. Cited 5 times so far (Crossref); 7 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: BTG/SERB Pharmaceuticals.
Abstract (original language)
High‐dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real‐world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati Collee of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID profiles: Zachary L Taylor, Tamara P Miller, Ethan A Poweleit, Ashley Chavana, Austin L Brown, Melanie B Bernhardt, Eric S Schafer, Maureen M O'Brien, Sharon M Castellino, Laura B Ramsey
Funding
- BTG/SERB Pharmaceuticals
Cite
APA
Taylor, Z. L., Miller, T. P., Board, S. G., Poweleit, E. A., Chavana, A., Weisnicht, A., Brown, A. L., Bernhardt, M. B., Schafer, E. S., O'Brien, M. M., Castellino, S. M., & Ramsey, L. B. (2025). What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31744
Vancouver
Taylor ZL, Miller TP, Board SG, Poweleit EA, Chavana A, Weisnicht A, et al. What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31744
BibTeX
@article{Taylor2025,
author = {Taylor, Zachary L and Miller, Tamara P and Board, Sarah G and Poweleit, Ethan A and Chavana, Ashley and Weisnicht, Allison and Brown, Austin L and Bernhardt, Melanie B and Schafer, Eric S and O'Brien, Maureen M and Castellino, Sharon M and Ramsey, Laura B},
title = {What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31744}
}
EUVIMED